THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies Eur Neurol 2014;71(suppl 1):4-9 - DOI:10.1159/000357742 Fig. 1. Effect of THC:CBD oromucosal spray on 5 specific driving-related ability dimensions in patients with moderate to severe resistant MS-related spasticity. * p = 0.0255 versus baseline. © 2014 S. Karger AG, Basel
THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies Eur Neurol 2014;71(suppl 1):4-9 - DOI:10.1159/000357742 Fig. 2. Effects of THC:CBD oromucosal spray and placebo on cognitive ability of MS patients with spasticity treated for 50 weeks. © 2014 S. Karger AG, Basel
THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies Eur Neurol 2014;71(suppl 1):4-9 - DOI:10.1159/000357742 Fig. 3. Effects of THC:CBD oromucosal spray and placebo on patient, physician and caregiver Global Impression of Change (GIC) in MS patients with spasticity treated for 50 weeks. * p = 0.0042; ** p = 0.0014; *** p < 0.001. © 2014 S. Karger AG, Basel